Neogenomics IncChange company Symbol lookupSelect an option...NEO Neogenomics IncGS Goldman Sachs Group IncONON On Holding AGXNCR Xencor IncALT Altimmune IncRZLT Rezolute IncBNKU MicroSectors? U.S. Big Banks Index 3X Leveraged ETNsSGFY Signify Health IncFRC First Republic BankBACK IMAC Holdings IncGo
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.
|
|
|
|
| |
Company Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 4.62x
- Price/Book (MRQ)
- 2.35x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in millions.
Company Officers
- Lynn A. TetraultChmn.
- Christopher SmithCEO
- Jeffrey Scott ShermanCFO
- Melody HarrisCorp.Exec.
- Vishal SikriCorp.Exec.
Address
- 9490 Neogenomics Way
- Fort Myers, FL 33912
- Phone: (239) 768-0600
- Fax: (775) 329-0852
- https://neogenomics.com/
Insider Trading
During the most recent quarter, 230 shares were bought in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.